Stock Events

Stock Events

Intra-Cellular Therapies 

R$125.76
46
+R$0+0% Friday 23:23

Statistics

Day High
0
Day Low
0
52W High
129.99
52W Low
0
Volume
0
Avg. Volume
185
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Apr 25
R$122.58
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

8MayExpected
Q1 2024
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q4 2025
Next
-0.3
-0.22
-0.14
-0.06
Expected EPS
N/A
Actual EPS
N/A

Financials

-10.87%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
3.82BRevenue
-414.95MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow I2TC34.SA. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap5.81B
Alkermes competes in the psychiatric and neurological disorder treatment space, offering products that directly compete with ITCI's offerings.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.78B
Acadia Pharmaceuticals specializes in CNS disorders, with products that compete in the schizophrenia and mental health treatment market, similar to ITCI.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap35.03B
Teva Pharmaceutical Industries has a broad portfolio that includes CNS treatments, competing with ITCI in the generic and branded drug markets for mental health.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson, through its Janssen Pharmaceuticals division, offers products that compete in the mental health and neurodegenerative diseases space, overlapping with ITCI's market.
Novartis
NVS
Mkt Cap297.32B
Novartis offers treatments for neurological conditions, competing with ITCI in research and development of new therapies for CNS disorders.
Pfizer
PFE
Mkt Cap161.09B
Pfizer has a diverse portfolio that includes treatments for CNS disorders, competing with ITCI in the development and marketing of drugs for mental health conditions.
Lilly(Eli) &
LLY
Mkt Cap837.36B
Eli Lilly has a strong focus on neurodegeneration and psychiatric disorders, making it a direct competitor to ITCI in the mental health drug market.
Merck
MRK
Mkt Cap298.84B
Merck & Co. invests in CNS disorder treatments, including schizophrenia and depression, areas where ITCI is also active.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb has a portfolio that includes psychiatric drugs, competing with ITCI in the development and commercialization of treatments for mental health disorders.

About

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company that develops and commercializes therapeutics and small molecule drugs for central nervous system (CNS), neuropsychiatric, and neurological disorders. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It distributes its products through third-party wholesale drug distributors. The company was founded in 2002 and is based in Bedminster, New Jersey. As of April 2, 2025, Intra-Cellular Therapies, Inc. operates as a subsidiary of Johnson & Johnson Innovative Medicine.
Show more...
CEO
Dr. Sharon Mates Ph.D.
Employees
860
Country
US
ISIN
BRI2TCBDR009

Listings

0 Comments

Share your thoughts

FAQ

What is Intra-Cellular Therapies stock price today?▼
The current price of I2TC34.SA is R$125.76 BRL — it has increased by +0% in the past 24 hours. Watch Intra-Cellular Therapies stock price performance more closely on the chart.
What is Intra-Cellular Therapies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Intra-Cellular Therapies stocks are traded under the ticker I2TC34.SA.
What is Intra-Cellular Therapies revenue for the last year?▼
Intra-Cellular Therapies revenue for the last year amounts to 3.82B BRL.
What is Intra-Cellular Therapies net income for the last year?▼
I2TC34.SA net income for the last year is -414.95M BRL.
Does Intra-Cellular Therapies pay dividends?▼
Yes, I2TC34.SA dividends are paid en. The last dividend per share was 122.58 BRL. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Intra-Cellular Therapies have?▼
As of April 07, 2026, the company has 860 employees.
In which sector is Intra-Cellular Therapies located?▼
Intra-Cellular Therapies operates in the Health Care sector.
When did Intra-Cellular Therapies complete a stock split?▼
Intra-Cellular Therapies has not had any recent stock splits.
Where is Intra-Cellular Therapies headquartered?▼
Intra-Cellular Therapies is headquartered in Bedminster, US.